Evidence map›Paper›PMID 36104509›Full record

ReviewNature reviews. Nephrology2022

Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.

Kunihiro Matsushita, Shoshana H Ballew, Angela Yee-Moon Wang, Robert Kalyesubula, Elke Schaeffner, Rajiv Agarwal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 412 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
412citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

412 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. LCN2 Associated With the Bidirectional Cardio-Kidney Link in Patients With Type 2 Diabetes and Cardiovascular-Kidney-Metabolic Syndrome.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  20. Article

352 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kunihiro MatsushitaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. kuni.matsushita@jhu.edu.ORCID 0000-0002-7179-718X
Shoshana H BallewDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Angela Yee-Moon WangDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China.ORCID 0000-0003-2508-7117
Robert KalyesubulaDepartments of Physiology and Internal Medicine, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda.
Elke SchaeffnerInstitute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-7925-4577
Rajiv AgarwalDepartment of Medicine, Indiana University School of Medicine and Veterans Affairs Medical Center, Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is defined by a low glomerular filtration rate or high albuminuria, and affects 15-20% of adults globally. CKD increases the risk of various adverse outcomes, but cardiovascular disease (CVD) is of particular relevance because it is the leading cause of death in this clinical population. CKD is associated with several CVD outcomes, including coronary heart disease, stroke, peripheral artery disease, arrhythmias, heart failure and venous thrombosis. Notably, CKD is particularly strongly associated with severe CVD outcomes such as CVD mortality, heart failure and lower extremity amputations. This broad impact of CKD on the cardiovascular system probably reflects the involvement of several pathophysiological mechanisms that link CKD to CVD development - shared risk factors (for example, diabetes and hypertension), changes in bone mineral metabolism, anaemia, volume overload, inflammation and the presence of uraemic toxins. Understanding the status of CKD is crucial for appropriate CVD risk prediction in CKD populations. However, major clinical guidelines are not consistent in their incorporation of CKD measures for CVD risk prediction. Mitigating CVD risk in patients with CKD effectively requires multidisciplinary care that involves nephrologists, cardiologists and other health professionals, as well as further work to address current research and implementation gaps.

Indexed as

Cardiovascular DiseasesHeart FailureRenal Insufficiency, ChronicAdultGlomerular Filtration RateHumansRisk Factors

Identifiers

PMID36104509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.